In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Mechanisms of improvement in claudication after exercise training in peripheral arterial disease

Session Ageing and heart disease: is 80 the new 60?

Speaker Jonathan Murrow

Event : ESC Congress 2015

  • Topic : cardiovascular disease in special populations
  • Sub-topic : Cardiovascular Disease in the Elderly
  • Session type : Rapid Fire Abstracts

Authors : J Murrow (Athens,US), J Brizendine (Athens,US), B Djire (Athens,US), HJ Young (Athens,US), KR Nilsson (Athens,US), KK Mccully (Athens,US)

J. Murrow1 , J. Brizendine1 , B. Djire1 , H.J. Young2 , K.R. Nilsson1 , K.K. McCully2 , 1Georgia Regents University - University of Georgia Medical Partnership - Athens - United States of America , 2University of Georgia, Kinesiology - Athens - United States of America ,

European Heart Journal ( 2015 ) 36 ( Abstract Supplement ), 166

Background: The mechanism of clinical improvement from supervised exercise training for claudication in peripheral arterial disease (PAD) is not well understood. Near infrared spectroscopy (NIRS) allows for real-time assessment of skeletal muscle blood flow. NIRS-derived post-exercise recovery of muscle oxygen consumption fit to a mono-exponential curve yields both a time constant (Tc) that is an index of mitochondrial capacity (i.e., oxygen use) as well as ability to measure reperfusion (T1/2 max, reflecting oxygen delivery).

Methods: To test the hypothesis that improvements in muscle oxygen use (training effects) rather than vascular oxygen delivery (microvascular effects) accounts for improvements in functional status after exercise training, we measured post-exercise NIRS-based assessment of mitochondrial capacity (Tc) and microcirculation (T1/2max) before and after a 12 week supervised exercise program in subjects with PAD. In addition, we tested whether ischemic calf pain versus calf-hypoxia measured by NIRS impacted training outcomes.

Results: Subjects with claudication from PAD trained thrice weekly for hour-long sessions over a 12 week period. Exercise intensity was determined by 15% reduction in resting skeletal muscle oxygenation by NIRS rather than by symptoms of pain. We randomly assigned subjects to NIRS-guided training (n=6, age 68.5±8.5, 33% female) versus traditional pain-based training (n=7, age 71.2±9.1 years, 29% female). Training cohorts were similar in baseline ankle-brachial index (ABI, 0.8±0.2 vs. 0.8±0.3, p=NS) and baseline symptom-free walking time on a Gardner graded treadmill test (3.5±1.8 vs. 1.7±0.9 min, p=NS). At the completion of 36 training sessions, NIRS-trained subjects demonstrated similar improvements in symptom-free walking time (mean 7.3±3.3 vs 6.3±3.5 min at 12 week follow up, p<0.01 for change from baseline and p=NS between cohorts) as the traditional pain-based cohort. In both NIRS-guided and pain-guided cohorts, measure of perfusion by ABI (p=0.3) and by T1/2 max for the entire cohort was unchanged (p=0.8). Meanwhile, mitochondrial oxidative capacity (Tc) improved in each PAD group (96.1±.0 to 50.0±8.8 sec, 75.2±43.0 to 59±21.0 sec, respectively; p<0.01 compared to baseline). T1/2 max was significantly higher in the PAD cohort compared with aged-matched controls without PAD (n=15; 94.0±52.2 vs. 17.9±8.3 sec, p<0.05).

Conclusions: Adaptations in mitochondrial oxidative capacity rather than improved tissue perfusion may account for improved walking times in subjects undergoing supervised exercise training in PAD.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are